Metabolic Dysfunction-Associated Steatohepatitis (MASH) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Metabolic Dysfunction-Associated Steatohepatitis Emerging Therapy and TPP Insights

Thelansis’s “Metabolic Dysfunction-Associated Steatohepatitis (MASH) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Metabolic Dysfunction-Associated Steatohepatitis Overview

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD) in which excess liver fat is accompanied by inflammation and hepatocellular injury, with fibrosis developing in some patients. The condition is closely associated with obesity, type 2 diabetes, dyslipidemia, and insulin resistance, and many patients remain asymptomatic until liver damage becomes advanced. Progressive fibrosis can lead to cirrhosis, hepatic decompensation, liver cancer, and transplantation. Management centers on lifestyle measures and weight reduction, with treatment increasingly guided by fibrosis severity and metabolic comorbidities. In the United States, resmetirom and semaglutide are approved for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. Despite these advances, durable disease control remains challenging, supporting continued development of FGF21 analogs, incretin-based therapies, and other metabolic and antifibrotic approaches.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)